283 related articles for article (PubMed ID: 34904839)
1. Preparation and Bioevaluation of
Ruan Q; Feng J; Jiang Y; Zhang X; Duan X; Wang Q; Yin G; Xiao D; Zhang J
Mol Pharm; 2022 Jan; 19(1):160-171. PubMed ID: 34904839
[TBL] [Abstract][Full Text] [Related]
2. Design and Development of
Lindner T; Altmann A; Krämer S; Kleist C; Loktev A; Kratochwil C; Giesel F; Mier W; Marme F; Debus J; Haberkorn U
J Nucl Med; 2020 Oct; 61(10):1507-1513. PubMed ID: 32169911
[TBL] [Abstract][Full Text] [Related]
3. A Simple Kit Formulation for Preparation and Exploratory Human Studies of a Novel
Ruan Q; Zhou C; Wang Q; Kang F; Jiang Y; Li G; Feng J; Zong S; Zhang J; Wang J
Mol Pharm; 2023 Jun; 20(6):2942-2950. PubMed ID: 37083360
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Preliminary Study of
Ma M; Yang G; Zhao M; Liu Y; Ge X; Jia B; Gao S
Mol Pharm; 2024 Feb; 21(2):735-744. PubMed ID: 38193393
[TBL] [Abstract][Full Text] [Related]
5. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics.
Wen X; Xu P; Shi M; Liu J; Zeng X; Zhang Y; Shi C; Li J; Guo Z; Zhang X; Khong PL; Chen X
Theranostics; 2022; 12(1):422-433. PubMed ID: 34987657
[No Abstract] [Full Text] [Related]
6. Design, Synthesis and Preclinical Assessment of
Trujillo-Benítez D; Luna-Gutiérrez M; Ferro-Flores G; Ocampo-García B; Santos-Cuevas C; Bravo-Villegas G; Morales-Ávila E; Cruz-Nova P; Díaz-Nieto L; García-Quiroz J; Azorín-Vega E; Rosato A; Meléndez-Alafort L
Molecules; 2022 Jan; 27(1):. PubMed ID: 35011496
[TBL] [Abstract][Full Text] [Related]
7. Formulation and Preclinical Testing of Tc-99m-Labeled HYNIC-Glc-FAPT as a FAP-Targeting Tumor Radiotracer.
Yang X; Li G; Ruan C; Hu K; Tang G
Bioconjug Chem; 2023 Nov; 34(11):2133-2143. PubMed ID: 37874952
[TBL] [Abstract][Full Text] [Related]
8. Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention.
Loktev A; Lindner T; Burger EM; Altmann A; Giesel F; Kratochwil C; Debus J; Marmé F; Jäger D; Mier W; Haberkorn U
J Nucl Med; 2019 Oct; 60(10):1421-1429. PubMed ID: 30850501
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Evaluation of
Ruan Q; Wang Q; Jiang Y; Feng J; Yin G; Zhang J
J Med Chem; 2023 Apr; 66(7):4952-4960. PubMed ID: 36972467
[TBL] [Abstract][Full Text] [Related]
10. Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an
Toms J; Kogler J; Maschauer S; Daniel C; Schmidkonz C; Kuwert T; Prante O
J Nucl Med; 2020 Dec; 61(12):1806-1813. PubMed ID: 32332144
[TBL] [Abstract][Full Text] [Related]
11. A novel molecular imaging probe [
Jiang Y; Tian Y; Feng B; Zhao T; Du L; Yu X; Zhao Q
Sci Rep; 2023 Mar; 13(1):3700. PubMed ID: 36879039
[TBL] [Abstract][Full Text] [Related]
12. Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma:
Watabe T; Liu Y; Kaneda-Nakashima K; Shirakami Y; Lindner T; Ooe K; Toyoshima A; Nagata K; Shimosegawa E; Haberkorn U; Kratochwil C; Shinohara A; Giesel F; Hatazawa J
J Nucl Med; 2020 Apr; 61(4):563-569. PubMed ID: 31586001
[TBL] [Abstract][Full Text] [Related]
13. Rational Design and Comparison of Novel
Meng L; Fang J; Zhang J; Li H; Xia D; Zhuang R; Chen H; Huang J; Li Y; Zhang X; Guo Z
J Med Chem; 2024 May; 67(10):8460-8472. PubMed ID: 38717104
[TBL] [Abstract][Full Text] [Related]
14. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy.
Yang T; Peng L; Qiu J; He X; Zhang D; Wu R; Liu J; Zhang X; Zha Z
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2331-2341. PubMed ID: 36864362
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation and a Pilot Clinical Positron Emission Tomography Imaging Study of [
Du X; Gu B; Wang X; Wang X; Ji M; Zhang J; He S; Xu X; Yang Z; Song S
Mol Pharm; 2024 Feb; 21(2):904-915. PubMed ID: 38179677
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Preclinical Evaluation of Novel
Ruan Q; Ding D; Diao L; Feng J; Yin G; Jiang Y; Wang Q; Han P; Jiang J; Zhang J
J Med Chem; 2024 Feb; 67(4):3190-3202. PubMed ID: 38320123
[TBL] [Abstract][Full Text] [Related]
17. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
[TBL] [Abstract][Full Text] [Related]
18. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
Xu M; Zhang P; Ding J; Chen J; Huo L; Liu Z
J Nucl Med; 2022 Jun; 63(6):952-958. PubMed ID: 34593598
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Biological Evaluation of Novel
Song X; Gan Q; Zhang X; Zhang J
Mol Pharm; 2019 Oct; 16(10):4213-4222. PubMed ID: 31424939
[TBL] [Abstract][Full Text] [Related]
20. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
Pang Y; Zhao L; Fang J; Chen J; Meng L; Sun L; Wu H; Guo Z; Lin Q; Chen H
J Nucl Med; 2023 Sep; 64(9):1449-1455. PubMed ID: 37321827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
